HC Wainwright Boosts Earnings Estimates for Bausch + Lomb

Bausch + Lomb Corporation (NYSE:BLCO) – HC Wainwright boosted their Q4 2026 earnings per share estimates for Bausch + Lomb in a report released on Monday, November 2nd. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of $0.34 for the quarter, up from their previous estimate of $0.28. HC Wainwright has a “Neutral” rating and a $22.00 price objective on the stock. The consensus estimate for Bausch + Lomb’s current full-year earnings is $0.94 per share. HC Wainwright also issued estimates for Bausch + Lomb’s Q3 2027 earnings at $0.25 EPS, Q4 2027 earnings at $0.35 EPS and FY2027 earnings at $1.05 EPS.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings data on Wednesday, October 28th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.13. The company had revenue of $1.38 billion during the quarter, compared to the consensus estimate of $1.37 billion. Bausch + Lomb had a positive return on equity of 5.01% and a negative net margin of 2.05%. The firm’s revenue was up 7.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.18 earnings per share.

BLCO has been the subject of several other research reports. Weiss Ratings upgraded shares of Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 21st. Zacks Research upgraded Bausch + Lomb from a “hold” rating to a “strong-buy” rating in a report on Friday, October 30th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $20.00 price objective on shares of Bausch + Lomb in a report on Thursday, October 29th. JPMorgan Chase & Co. lifted their target price on Bausch + Lomb from $16.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, October 29th. Finally, Barclays raised shares of Bausch + Lomb to a “strong-buy” rating in a report on Wednesday, October 7th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $20.83.

Bausch + Lomb Stock Performance

NYSE BLCO opened at $20.01 on Wednesday. Bausch + Lomb has a 12 month low of $14.44 and a 12 month high of $21.36. The company has a current ratio of 1.56, a quick ratio of 1.04 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $7.15 billion, a PE ratio of -64.55, a price-to-earnings-growth ratio of 0.53 and a beta of 0.52. The business’s 50-day moving average price is $17.46 and its two-hundred day moving average price is $16.71.

Institutional Investors Weigh In On Bausch + Lomb

Several large investors have recently added to or reduced their stakes in BLCO. Whitebox Advisors LLC increased its holdings in shares of Bausch + Lomb by 15.8% in the 1st quarter. Whitebox Advisors LLC now owns 1,101,854 shares of the company’s stock worth $17,519,000 after buying an additional 150,641 shares during the last quarter. Beach Point Capital Management LP bought a new stake in shares of Bausch + Lomb in the 3rd quarter valued at about $5,882,000. Sei Investments Co. lifted its position in Bausch + Lomb by 100.0% in the first quarter. Sei Investments Co. now owns 139,266 shares of the company’s stock valued at $2,214,000 after purchasing an additional 69,633 shares during the last quarter. Engineers Gate Manager LP purchased a new stake in Bausch + Lomb during the 2nd quarter valued at $1,479,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Bausch + Lomb by 13.2% during the first quarter. Dimensional Fund Advisors LP now owns 85,779 shares of the company’s stock worth $1,362,000 after purchasing an additional 9,971 shares during the period. Institutional investors own 11.07% of the company’s stock.

Insider Activity at Bausch + Lomb

In related news, CAO Frederick Munsch sold 112,015 shares of Bausch + Lomb stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $20.48, for a total value of $2,294,067.20. Following the completion of the transaction, the chief accounting officer directly owned 45,831 shares in the company, valued at approximately $938,618.88. The trade was a 70.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Eschenbach Andrew C. Von sold 12,500 shares of Bausch + Lomb stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $16.50, for a total value of $206,250.00. Following the completion of the transaction, the director owned 69,792 shares of the company’s stock, valued at approximately $1,151,568. This trade represents a 15.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 183,474 shares of company stock valued at $3,488,437. 1.45% of the stock is owned by insiders.

Key Bausch + Lomb News

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Analyst earnings estimates increased: HC Wainwright raised its forecasts for Q4 2026 EPS to $0.34 from $0.28 and FY2027 EPS to $1.05 from $0.89. It also lifted estimates for Q3 and Q4 2027. Higher projections suggest improving expectations for future earnings.
• Neutral Sentiment: Rating remains cautious: Despite the estimate increases, HC Wainwright kept its Neutral rating and $22 price target after recently downgrading BLCO from Buy. The target is above the $20.01 reference price, but the rating signals limited conviction in outperformance. Bausch + Lomb Stock Rating Lowered by HC Wainwright
• Negative Sentiment: Significant insider sale: Chief Accounting Officer Frederick Munsch sold 112,015 shares for about $2.29 million, cutting his reported holdings by roughly 71%. The sale could weigh on sentiment, although insider transactions do not necessarily indicate a negative outlook. Bausch + Lomb CAO Sells Shares

Bausch + Lomb Company Profile

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.